Company Overview of Novartis Vaccines and Diagnostics, Inc.
Novartis Vaccines and Diagnostics, Inc. manufactures vaccines. The company offers pharmaceuticals products in the therapeutic areas of hypertension, metabolism, infectious diseases, neuroscience, oncology, ophthalmology, respiratory, rheumatology and auto immunity, transplantation, and others. It also offers ophthalmic surgical portfolio that includes technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts, including refractive errors, such as presbyopia and astigmatism; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; treatment options f...
350 Massachusetts Avenue
Cambridge, MA 02139
Founded in 1986
Key Executives for Novartis Vaccines and Diagnostics, Inc.
Deputy Chief Financial Officer
Head of Novartis Group Quality
Compensation as of Fiscal Year 2015.
Novartis Vaccines and Diagnostics, Inc. Key Developments
Novartis Vaccines & Diagnostics Inc. Wins $3.62 Million Federal Contract from the U.S. Health and Human Services Department's Centers for Disease Control and Prevention
Jan 10 16
Novartis Vaccines & Diagnostics Inc. won a federal contract valued at up to $3.62 million from the U.S. Health and Human Services Department's Centers for Disease Control and Prevention for the supply of pediatric flu vaccines for the National Center for Immunization and Respiratory Diseases in Atlanta.
Novartis Vaccines and Diagnostics, Inc. Wins $22.64 Million Federal Contract
Jun 21 15
Novartis Vaccines and Diagnostics, Inc. was awarded a firm-fixed-price federal contract modification valued at up to $22,644,000 by the Defense Logistics Agency Troop Support, Philadelphia, for vaccines to be used by the U.S. Army, U.S. Navy, U.S. Air U.S. Force and U.S. Marine Corps in Massachusetts and United Kingdom. The contract has one option year.
Microbix Biosystems Inc. Updates its VIRUSMAX Patent Infringement Lawsuit Against Novartis Vaccines and Diagnostics
Mar 26 15
Microbix Biosystems Inc. announced that the Court of Dusseldorf, Germany has dismissed its VIRUSMAX(r) patent infringement lawsuit against Novartis Vaccines and Diagnostics without prejudice. Microbix successfully obtained VIRUSMAX patents in 21 countries between 2006 and 2011 claiming methods for the improvement of virus yields in the manufacture of influenza and related vaccines. In 2010 Novartis filed an Opposition at the European Patent Office (EPO) in Munich against Microbix' European Patent 1 636 352 B1. The EPO rejected the Opposition at its Hearing in January 2014. The EPO has not yet addressed Novartis' appeal of its decision. In July 2014, Microbix filed a lawsuit against Novartis for infringement of its patent in Germany, based on evidence published on the internet by students disclosing material authored by Novartis employees in the US and the UK, which Microbix discovered in November 2013. Microbix endeavoured to obtain further evidence of infringement of the Italian portion of the EPO Patent by filing an additional action against Novartis in July 2014 in the Court of Rome, Italy. The Court of Rome subsequently granted Microbix a Seizure Order, which allowed Court officials to seize Novartis' regulatory, development and manufacturing records at their Italian manufacturing facilities, in July 2014. Meanwhile, Novartis filed an action in Italy seeking nullification of Microbix' Italian patent, an action to which Microbix is responding. Novartis filed multiple motions with the Court of Rome demanding additional confidentiality provisions, which delayed the review of documents by Microbix. The Court of Dusseldorf has dismissed the infringement action without prejudice on March 26. This decision is fully appealable. Microbix' counsel is completing the examination of Novartis' records and will determine whether to file its infringement complaint based on the outcome of its review.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|